NetworkNewsBreaks – Longeveron Inc. (NASDAQ: LGV

NetworkNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) to Share CLEAR MIND Study Results in Featured Research Oral Presentation at 2024 AAIC

Longeveron (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it has been accepted for a Featured Research Oral Presentation to present the company’s CLEAR MIND Phase 2a study results. A Phase 2a randomized clinical trial, CLEAR-MIND is evaluating Lomecel-B(TM) in mild Alzheimer’s disease. In addition to the study results, Longeveron has been accepted for a poster presentation at the 2024 Alzheimer’s Association International Conference (“AAIC”) taking place online and in Philadelphia, Pennsylvania, from July 28 – August 1, 2024. “We are extremely excited to share the full study results of our CLEAR-MIND trial at the AAIC meeting this year and have the opportunity to present at the leading forum for Alzheimer’s disease clinical investigation,” said Wa’el Hashad, CEO of Longeveron.

NOTE TO INVESTORS: The latest news and updates relating to LGVN are available in the company’s newsroom at https://nnw.fm/LGVN

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer